Is Eli Lilly (LLY) a Buy Post Stellar Q2 Earnings & Raised View?
https://www.zacks.com/stock/news/2321929/is-eli-lilly-lly-a-buy-post-stellar-q2-earnings-raised-view?cid=CS-ZC-FT-analyst_blog|most_popular_stocks-2321929
Aug 14, 2024 - Eli Lilly (LLY) is a great stock to have in one's portfolio currently based on its strong overall financial performance and robust drug pipeline.
0
Here's How to Play Novo Nordisk (NVO) After Q2 Earnings Miss
https://www.zacks.com/stock/news/2321469/here-s-how-to-play-novo-nordisk-nvo-after-q2-earnings-miss?cid=CS-ZC-FT-analyst_blog|most_popular_stocks-2321469
Aug 13, 2024 - Novo Nordisk (NVO) is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs. New investors should utilize the existing opportunity to make an entry.
0
Amgen (AMGN) Reports Q2 Earnings: What Key Metrics Have to Say
https://www.zacks.com/stock/news/2317451/amgen-amgn-reports-q2-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2317451
Aug 06, 2024 - The headline numbers for Amgen (AMGN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
0
Amgen (AMGN) Q2 Earnings and Revenues Beat Estimates
https://www.zacks.com/stock/news/2317350/amgen-amgn-q2-earnings-and-revenues-beat-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2317350
Aug 06, 2024 - Amgen (AMGN) delivered earnings and revenue surprises of 0.81% and 0.98%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
0
Amgen (AMGN) Advances While Market Declines: Some Information for Investors
https://www.zacks.com/stock/news/2314714/amgen-amgn-advances-while-market-declines-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2314714
Aug 01, 2024 - Amgen (AMGN) closed at $335.53 in the latest trading session, marking a +0.92% move from the prior day.
0
What Awaits Biogen (BIIB) in Q2 Earnings Post Leqembi Setback?
https://www.zacks.com/stock/news/2311049/what-awaits-biogen-biib-in-q2-earnings-post-leqembi-setback?cid=CS-ZC-FT-analyst_blog|earnings_preview-2311049
Jul 29, 2024 - Biogen's (BIIB) sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been hurt by increased competition.
0
Amgen (AMGN) Advances But Underperforms Market: Key Facts
https://www.zacks.com/stock/news/2310378/amgen-amgn-advances-but-underperforms-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2310378
Jul 26, 2024 - In the closing of the recent trading day, Amgen (AMGN) stood at $334.85, denoting a +0.16% change from the preceding trading day.
0
What's in Store for ADMA Biologics (ADMA) in Q2 Earnings?
https://www.zacks.com/stock/news/2306129/what-s-in-store-for-adma-biologics-adma-in-q2-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2306129
Jul 22, 2024 - On ADMA Biologics' (ADMA) second-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.
0
Q2 Earnings Season Scorecard, Economic Outlook and Analyst Reports for NVIDIA, Meta & Others
https://www.zacks.com/commentary/2304617/q2-earnings-season-scorecard-economic-outlook-and-analyst-reports-for-nvidia-meta-others?cid=CS-ZC-FT-research_daily-2304617
Jul 18, 2024 - Today's Research Daily features the Q2 earnings season scorecard and fresh research reports on NVIDIA (NVDA), Meta (META), Amgen and others.
0
What Is the Dividend Payout for Amgen Stock?
https://www.fool.com/investing/2024/07/15/what-is-the-dividend-payout-for-amgen-stock/?source=iedfolrf0000001
Jul 15, 2024 - Amgen offers a packed pipeline and healthy dividend distributions.
0